Hepatitis C treatment in combination with amiodarone: risk of severe bradycardia

Patients receiving combination therapy with simeprevir (Olysio) and sofosbuvir (Sovaldi) should avoid concomitant use of amiodarone, unless other antiarrhythmics cannot be given.

Following the May issue of Drug Safety Update, the MHRA has extended its advice regarding the use of sofosbuvir combination therapy with amiodarone, to now include simeprevir.

Advice for monitoring patients receiving concomitant amiodarone and with cardiac rhythm disorders and hepatitis C can be found here.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more